Esophageal adenocarcinoma (EAC) is resistant to standard chemoradiation treatments and few targeted therapies are available. We used large-scale tissue profiling and pharmacogenetic analyses to identify deregulated signaling pathways in EAC tissues that might be targeted to slow tumor growth or progression.